Peptide therapeutics for rare genetic metabolic diseases

Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Year Invested: 2010
Location: Boston, Mass.

Recent News

December 6, 2018
Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome

November 15, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018

November 9, 2018
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results

Read More News

Associated Team Members

Neil Exter